Day: September 24, 2020

Target enrollment milestone reached in the Phase 3 EMERALD studyLife cycle planning advancing in parallel with current Phase 3 monotherapy programWALTHAM, Mass. and FLORENCE, Italy, Sept. 24, 2020 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.EMERALD Phase 3 StudyThe target enrollment milestone has been reached in the Phase 3 EMERALD clinical trial of elacestrant. Elacestrant is an oral Selective Estrogen Receptor Degrader (SERD) that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer. The study reached its enrollment goal of 466 patients overall, including 220 (47%) with tumors harboring an ESR1 mutation as detected in circulating tumor DNA by the Guardant...

ISSAQUAH, Wash., Sept. 24, 2020 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year, ended August 30, 2020.Net sales for the quarter increased 12.5 percent, to $52.28 billion from $46.45 billion last year. Net sales for the fiscal year increased 9.3 percent, to $163.22 billion from $149.35 billion last year.Comparable sales for the fourth quarter and the fiscal year were as follows:*Excluding the impacts from changes in gasoline prices and foreign exchange.Net income for the fourth quarter was $1.389 billion, or $3.13 per diluted share, compared to $1.097 billion, or $2.47 per diluted share last year. This year’s fourth quarter was negatively impacted by incremental expense related to COVID-19 premium...

– Virtual event to take place from 8:00 a.m. to 9:30 a.m. EDT –HAMILTON, Bermuda, Sept. 24, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company’s virtual Rilonacept Analyst Day will now take place on Tuesday, September 29th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time.The event will feature presentations from the Kiniksa management team on the market opportunity for rilonacept in recurrent pericarditis as well as the company’s continued commercial preparations and launch strategy. Additionally, guest speaker Paul Cremer, MD, Cardiovascular Medicine, Cleveland Clinic, will review the...

L’ASSOMPTION, Quebec, Sept. 24, 2020 (GLOBE NEWSWIRE) — Corporation Terranueva (CSE : TEQ) ) (the “Corporation” or “Terranueva”), one of the 6 companies in Québec holding a licence from Health Canada to develop cannabis products for medical and recreational purposes, is pleased to announce that Economic Development Canada (“EDC”) has granted a loan of $500,000 to the business to support its day-to-day operations.This assistance from EDC comes from the Regional Relief and Recovery Fund (“RRRFˮ), relating to the measures of Canada’s Economic Response Plan aimed at responding effectively to the COVID-19 pandemic.“The COVID-19 pandemic has placed significant pressure on corporate liquidity. We are therefore very happy to be able to count on this invaluable financial support from EDC via the RRRFˮ, underlines Francisco Perez Junior,...

L’ASSOMPTION, Québec, 24 sept. 2020 (GLOBE NEWSWIRE) — Corporation Terranueva (CSE : TEQ) (la « Société » ou « Terranueva »), une des 6 sociétés québécoises détentrices d’une licence de Santé Canada permettant de développer des produits médicinaux et récréatifs à base de cannabis, est heureuse d’annoncer que Développement Économique Canada (« DEC ») a accordé un prêt de 500 000$ à l’entreprise afin de soutenir ses opérations courantes.Cette aide du DEC provient du Fonds d’aide et de relance régionale (« FARR »), lequel complète les mesures du Plan d’intervention économique du Canada afin de répondre efficacement à la COVID-19.« La pandémie de COVID-19 a entrainé une importante pression sur les liquidités des entreprises. Nous sommes ainsi très heureux de pouvoir compter sur ce précieux soutien financier de DEC via le FARR...

First quarter sales of $401 million, down 26% from the prior year reflecting the impact of COVID-19First quarter GAAP diluted loss per share from continuing operations of $(0.40)Adjusted diluted earnings per share from continuing operations of $0.17, which exclude the impact of the Composites sale and other itemsWOOD DALE, Ill., Sept. 24, 2020 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR) today reported first quarter Fiscal Year 2021 consolidated sales of $400.8 million and loss from continuing operations of $13.9 million, or $0.40 per diluted share. For the first quarter of the prior year, the Company reported sales of $541.5 million and income from continuing operations of $17.1 million, or $0.49 per diluted share. Our adjusted diluted earnings per share from continuing operations in the first quarter of Fiscal Year 2021 were $0.17...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).ProQR’s presentation at Ophthalmology Futures Retina ForumPresentation title: Advancements in Inherited Retinal Diseases ManagementPresenter: Aniz Girach, MD, Chief Medical Officer of ProQRDate: September 30, 2020ProQR’s presentations at EuretinaPresentation title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10)Presenter: Stephen...

Lille, France; Cambridge, M.A.; September 24, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the first patient first visit for ELATIVE, the global, pivotal, Phase 3 study evaluating elafibranor in Primary Biliary Cholangitis (PBC).ELATIVE is a randomized, double blind, placebo-controlled, global multicenter Phase 3 study evaluating the efficacy and safety of elafibranor, a dual PPAR alpha and delta agonist, in PBC. The primary endpoint will evaluate the response to treatment defined by alkaline phosphatase (ALP) < 1.67 x upper limit of normal (ULN), total bilirubin (TB) ≤ ULN and ALP decrease ≥ 15%. Key secondary endpoints will include the effect of elafibranor on normalization of ALP and change in pruritus...

TORONTO, Sept. 24, 2020 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres”) (TSX:SRU.UN) announced today that the trustees of SmartCentres have declared a distribution for the month of September 2020 of CDN $0.15417 per trust unit, representing CDN $1.85 per unit on an annualized basis. Payment will be made on October 15, 2020 to unitholders of record on September 30, 2020.About SmartCentresSmartCentres Real Estate Investment Trust is one of Canada’s largest fully integrated REITs, with a best-in-class portfolio featuring 166 strategically located properties in communities across the country. SmartCentres has $10.4 billion in assets and owns over 34.2 million square feet of income producing value-oriented retail space with 97.8% occupancy, on 3,500 acres of owned land across Canada.SmartCentres continues...

VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) — AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies. AbCellera will generate panels of antibodies for multiple therapeutic targets identified by IGM using       its full-stack, AI-powered antibody discovery technology, and IGM will have the rights to develop and commercialize the novel antibodies resulting from this collaboration. Financial terms of the collaboration were not disclosed.“We believe that AbCellera’s technology will assist us in rapidly identifying the best antibodies against a large number of agonist targets, as well as other historically...